Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Enterprise Value (2022 - 2025)

Axsome Therapeutics' Enterprise Value history spans 4 years, with the latest figure at -$322.9 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 2.39% year-over-year to -$322.9 million; the TTM value through Dec 2025 reached -$322.9 million, down 2.39%, while the annual FY2025 figure was -$322.9 million, 2.39% down from the prior year.
  • Enterprise Value for Q4 2025 was -$322.9 million at Axsome Therapeutics, up from -$325.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$73.4 million in Q2 2022 and bottomed at -$437.1 million in Q2 2023.
  • The 4-year median for Enterprise Value is -$315.5 million (2024), against an average of -$288.4 million.
  • The largest annual shift saw Enterprise Value plummeted 495.55% in 2023 before it grew 27.78% in 2024.
  • A 4-year view of Enterprise Value shows it stood at -$200.8 million in 2022, then crashed by 92.29% to -$386.2 million in 2023, then rose by 18.34% to -$315.4 million in 2024, then decreased by 2.39% to -$322.9 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Enterprise Value are -$322.9 million (Q4 2025), -$325.3 million (Q3 2025), and -$303.0 million (Q2 2025).